Description Contributors Gil Rabinovici, M.D., Edward Fein and Pearl Landrith Distinguished Professor, University of California San Francisco Department of Neurology Dr. Rabinovici is the Edward Fein and Pearl Landrith Distinguished Professor in the University of California San Francisco (UCSF) Department of Neurology. He received his Bachelor’s degree from Stanford University and MD from Northwestern University Medical School. He completed an internship in internal medicine at Stanford University, neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the UCSF Memory and Aging Center (MAC). Dr. Rabinovici’s research investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and to study the biology of neurodegenerative diseases, with the goal of accelerating treatment development. He leads the MAC PET imaging program and is Associate Director of the UCSF Alzheimer’s Disease Center. Dr. Rabinovici is principal investigator of Imaging Dementia: Evidence for Amyloid Scanning (IDEAS), a U.S.-wide study to assess the clinical utility of amyloid PET in 18,500 patients with MCI/dementia of uncertain etiology. He is co-PI and PET Core Director of the multi-site Longitudinal Evaluation of Early-Onset Alzheimer’s Disease Study (LEADS).
Contributors Gil Rabinovici, M.D., Edward Fein and Pearl Landrith Distinguished Professor, University of California San Francisco Department of Neurology Dr. Rabinovici is the Edward Fein and Pearl Landrith Distinguished Professor in the University of California San Francisco (UCSF) Department of Neurology. He received his Bachelor’s degree from Stanford University and MD from Northwestern University Medical School. He completed an internship in internal medicine at Stanford University, neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the UCSF Memory and Aging Center (MAC). Dr. Rabinovici’s research investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and to study the biology of neurodegenerative diseases, with the goal of accelerating treatment development. He leads the MAC PET imaging program and is Associate Director of the UCSF Alzheimer’s Disease Center. Dr. Rabinovici is principal investigator of Imaging Dementia: Evidence for Amyloid Scanning (IDEAS), a U.S.-wide study to assess the clinical utility of amyloid PET in 18,500 patients with MCI/dementia of uncertain etiology. He is co-PI and PET Core Director of the multi-site Longitudinal Evaluation of Early-Onset Alzheimer’s Disease Study (LEADS).